U. S. Federal Trade Commission (FTC) on Thursday announced that generic drug maker Mylan Inc's proposed deal with India's Strides Arcolab Ltd to buy its Agila unit had been approved.

The Agila acquisition deal, which has already been approved by Indian authorities, was valued at US$1.6 billion at the time of its announcement in February this year.

American antitrust authorities approved the deal, attached some conditions. Giving its approval, the FTC said the companies would have to divest assets required to make eleven generic injectable drugs.

The list of assets that the companies will have to divest includes, detoxifying agent mesna, acetylcysteine injection, anti-arrhythmic heart drug amiodarone hydrochloride, hypertension drug labetalol hydrochloride, surgical anesthetic etomidate injection, and cancer drug fluorouracil.

Indian authorities approved the deal on 3rd of September, following delays due to concerns that it could hurt the supply of important drugs in the country.

Pennsylvania-based Mylan is one of the world's largest generic drug makers, and the acquisition of Bangalore-based Agila is expected to double its already massive injectable drugs portfolio.